Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

被引:194
作者
Brilakis, ES
McConnell, JP
Lennon, RJ
Elesber, AA
Meyer, JG
Berger, PB [1 ]
机构
[1] Duke Clin Res Inst, Div Cardiovasc Dis, Durham, NC 27715 USA
[2] Mayo Clin & Mayo Fdn, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[4] Mayo Clin, Div Biostat, Rochester, MN USA
关键词
lipoprotein-associated phospholipase A2; C-reactive protein; acute myocardial infarction; coronary disease;
D O I
10.1093/eurheartj/ehi010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We aimed to evaluate the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) with coronary artery disease (CAD) risk factors, with the severity of angiographic CAD, and with the incidence of major adverse events. Methods and results We measured Lp-PLA2 levels in 504 consecutive patients undergoing clinically indicated coronary angiography. Mean age was 60 +/- 11 years and 38 % were women. The mean (+/- SD) Lp-PLA2 level (ng/mL) was 245 +/- 91. Lp-PLA2 levels correlated with mate gender, LDL, HDL, and total cholesterol, fibrinogen, and creatinine. Lp-PLA2 levels correlated with the extent of angiographic CAD on univariate but not on multivariable analysis. During a median follow-up of 4.0 years, 72 major adverse events occurred in 61 of 466 (13 %) contacted patients (20 deaths, 14 myocardial infarctions, 28 coronary revascularizations, and 10 strokes). Higher Lp-PLA2 levels were associated with a greater risk of events: the hazard ratio per SD was 1.28 (95 % Cl 1.06-1.54, P = 0.009), and remained significant after adjusting for clinical and lipid variables and C-reactive protein. Conclusion Higher Lp-PLA2 levels were associated with a higher incidence of major adverse events at follow-up, independently of traditional CAD risk factors and C-reactive protein.
引用
收藏
页码:137 / 144
页数:8
相关论文
共 12 条
[1]   Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, J ;
Folsom, AR ;
Heiss, G ;
Sharrett, AR .
CIRCULATION, 2004, 109 (07) :837-842
[2]   A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women [J].
Blake, GJ ;
Dada, N ;
Fox, JC ;
Manson, JE ;
Ridker, PM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (05) :1302-1306
[3]   Potent, orally active inhibitors of lipoprotein-associated phospholipase A2:: 1-(biphenylmethylamidoalkyl)-pyrimidones [J].
Boyd, HF ;
Fell, SCM ;
Hickey, DMB ;
Ife, RJ ;
Leach, CA ;
Macphee, CH ;
Milliner, KJ ;
Pinto, IL ;
Rawlings, DA ;
Smith, SA ;
Stansfield, IG ;
Stanway, SJ ;
Theobald, CJ ;
Whittaker, CM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (01) :51-55
[4]   Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase:: a potential new risk factor for coronary artery disease [J].
Caslake, MJ ;
Packard, CJ ;
Suckling, KE ;
Holmes, SD ;
Chamberlain, P ;
Macphee, CH .
ATHEROSCLEROSIS, 2000, 150 (02) :413-419
[5]   Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions [J].
Häkkinen, T ;
Luoma, JS ;
Hiltunen, MO ;
Macphee, CH ;
Milliner, KJ ;
Patel, L ;
Rice, SQ ;
Tew, DG ;
Karkola, K ;
Ylä-Herttuala, S .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (12) :2909-2917
[6]  
KILLIP T, 1981, CIRCULATION, V63, P1
[7]   Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein:: use of a novel inhibitor [J].
Macphee, CH ;
Moores, KE ;
Boyd, HF ;
Dhanak, D ;
Ife, RJ ;
Leach, CA ;
Leake, DS ;
Milliner, KJ ;
Patterson, RA ;
Suckling, KE ;
Tew, DG ;
Hickey, DMB .
BIOCHEMICAL JOURNAL, 1999, 338 :479-487
[8]  
Macphee Colin H., 2001, Current Opinion in Pharmacology, V1, P121, DOI 10.1016/S1471-4892(01)00024-8
[9]   Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. [J].
Packard, CJ ;
O'Reilly, DSJ ;
Caslake, MJ ;
McMahon, AD ;
Ford, I ;
Cooney, J ;
Macphee, CH ;
Suckling, KE ;
Krishna, M ;
Wilkinson, FE ;
Rumley, A ;
Lowe, GDO .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1148-1155
[10]   Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins [J].
Tew, DG ;
Southan, C ;
Rice, SQJ ;
Lawrence, GMP ;
Li, HD ;
Boyd, HF ;
Moores, K ;
Gloger, IS ;
Macphee, CH .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (04) :591-599